Press Releases

Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets

SOUTH SAN FRANCISCO, January 9, 2023
ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

SOUTH SAN FRANCISCO, December 12, 2022
Cellworks Therapy Biosimulation Study Reveals Promising New Biomarkers for TMZ Resistance in Glioblastoma Patients

SOUTH SAN FRANCISCO, November 22, 2022
Cellworks Wins Dell Technologies The Challengers 2022 Innovative Business of the Year Award

SOUTH SAN FRANCISCO, Calif., September 7, 2022
Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors

SOUTH SAN FRANCISCO, Calif., August 9, 2022
ASCO 2022 : Cellworks Singula™ TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies

CHICAGO, June 6, 2022
ASCO 2022 : Cellworks Singula™ TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors

CHICAGO, June 6, 2022
ASH 2021: myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients than Physician Prescribed Treatment

ATLANTA, Georgia, December 14, 2021
ASH 2021: Cellworks Personalized Therapy Biosimulation Study Identifies Novel Biomarkers Predictive of Response in AML Patients

ATLANTA, Georgia, December 14, 2021
ASH 2021: Cellworks Personalized Therapy Biosimulation Study Identifies Novel Biomarkers Predictive of Response in Resistance Cases of MCL

ATLANTA, Georgia, December 14, 2021
ASH 2021: Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response

ATLANTA, Georgia, December 14, 2021
WCLC 2021 : Cellworks Clinical Trial Results Presented at IASLC 2021
World Conference on Lung Cancer

SOUTH SAN FRANCISCO, Calif., September 13, 2021
ASCO 2021 : Cellworks Singula™ Delivers Superior OS and DFS Predictions for Brain Cancer Patients in myCare-022-03 Clinical Trial

SOUTH SAN FRANCISCO, Calif., June 4, 2021
ASCO 2021 : Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients

SOUTH SAN FRANCISCO, Calif., June 4, 2021
ASCO 2021 : Cellworks Singula™ Accurately Predicts Clinical Outcome from Treatments in Patients with NSCLC

SOUTH SAN FRANCISCO, Calif., June 4, 2021
ASH 2020 : Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients

SOUTH SAN FRANCISCO, Calif., December 7, 2020
ASH 2020 : Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

SOUTH SAN FRANCISCO, Calif., December 7, 2020
ASH 2020 : Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

SOUTH SAN FRANCISCO, Calif., December 7, 2020
ASH 2020 : Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with
Monosomy 7

SOUTH SAN FRANCISCO, Calif., December 7, 2020
ASCO 2020 : myCare Clinical Studies Show Cellworks Singula™Achieves Superior Therapy Response Predictions for Brain Cancer Patients

SOUTH SAN FRANCISCO, Calif., May 29, 2020
ASCO 2020 : Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments

SOUTH SAN FRANCISCO, Calif., May 14, 2020
ASCO 2020 : Cellworks Singula™ Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy

SOUTH SAN FRANCISCO, Calif., May 14, 2020
Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy

SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE)
ASCO 2019 : Cellworks myCare™ Clinical Trial Transforms NGS Data into Personalized Cancer Therapy Actions

CHICAGO, 2019 ASCO Annual Meeting, June 3, 2019
ASH 2018 : Cellworks Study Predicted Non-Response to Azacitidine in MDS Patients with 100% Accuracy using AI-Driven Biosimulation

SAN DIEGO, Calif. December 2, 2018
ASH 2018 : Cellworks AI-Driven Biosimulation Predicted Chemo-resistance in AML and MDS Patients with 90% Accuracy

SAN DIEGO, Calif. December 2, 2018
Cellworks to Present 10 Abstracts at 2018 American Society of Hematology Annual Meeting

SAN JOSE, Calif. November 19, 2018

Former UnitedHealth Group Cancer Director Dr. Lee Newcomer Joins Cellworks Board of Directors

SAN JOSE, Calif., October 17, 2018
Dr. Allen Lichter Joins Cellworks Group Board of Directors

SAN JOSE, Calif., May 31, 2018

STAY INFORMED

Top